Mao Dongdong, Deng Yanli, Zhang Leixiao, Zhao Ying, Li Ying, Wang Fei
Hospital of Chengdu University of Traditional Chinese Medicine/Clinical Medical College of Chengdu University of Traditional Chinese Medicine.
Sichuan Second Chinese Medicine Hospital.
Medicine (Baltimore). 2020 Jun 12;99(24):e20676. doi: 10.1097/MD.0000000000020676.
Chronic bronchitis (CB) is a clinically common and recurrent respiratory disease. However, many trials have shown that acupuncture can effectively treat CB. There is currently no systematic review of this therapy. The plan is to evaluate the effectiveness and safety of this treatment in patients with CB.
This systematic evaluation will entail an electronic and manual search of all acupuncture for CB from inception to December 31, 2020, regardless of the publication status or language. Databases include PubMed, Embase, Springer, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trial Registration Platform, the Chinese Medicine Database, the China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the China Science Journal Database, and the Wanfang Database. Other sources of information, including bibliographies and meeting minutes for identified publications, will also be searched. A manual search for grey literature, including unpublished conference articles will be performed. Additionally, any clinical randomized controlled trials related to acupuncture for CB, regardless of the publication status and language limitations, will be included in the study. Study selection, data extraction, and research quality assessments will be conducted independently by 2 researchers. The main result was the Change in cystic fibrosis transmembrane conductance regulator function as measured by sweat chloride analysis or treatment effect. Secondary outcomes included Quality of life (eg, SF-36), change in Breathlessness, Cough, and Sputum Scale score, follow-up relapse rate, and adverse events. The system searches for randomized controlled trials of this therapy for CB. Implement the Cochrane RevMan V5.3 bias assessment tool to assess bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean difference, standard mean deviation, and binary data will be used to represent continuous results.
This study will provide a comprehensive review and evaluation of the available evidence for the treatment of CB using this therapy.
This study will provide new evidence to evaluate the effectiveness and side effects of acupuncture on CB. Because the data are not personalized, no formal ethical approval is required.
CRD42020170287.
慢性支气管炎(CB)是一种临床常见且反复发作的呼吸道疾病。然而,许多试验表明针灸可以有效治疗慢性支气管炎。目前尚无对该疗法的系统评价。本计划旨在评估该疗法对慢性支气管炎患者的有效性和安全性。
本系统评价将对从开始到2020年12月31日所有关于针灸治疗慢性支气管炎的研究进行电子和手动检索,无论其发表状态或语言如何。数据库包括PubMed、Embase、Springer、Web of Science、Cochrane图书馆、世界卫生组织国际临床试验注册平台、中医药数据库、中国知网、中国生物医学文献数据库、中国科学期刊数据库和万方数据库。还将检索其他信息来源,包括已识别出版物的参考文献和会议记录。将对灰色文献进行手动检索,包括未发表的会议文章。此外,任何与针灸治疗慢性支气管炎相关的临床随机对照试验,无论其发表状态和语言限制如何,都将纳入本研究。研究选择、数据提取和研究质量评估将由两名研究人员独立进行。主要结果是通过汗液氯化物分析或治疗效果测量的囊性纤维化跨膜传导调节因子功能的变化。次要结果包括生活质量(如SF-36)、呼吸困难、咳嗽和痰液量表评分的变化、随访复发率和不良事件。系统检索该疗法治疗慢性支气管炎的随机对照试验。使用Cochrane RevMan V5.3偏倚评估工具评估偏倚风险、数据整合风险、荟萃分析风险和亚组分析风险(如果条件满足)。均值差、标准化均值差和二分类数据将用于表示连续结果。
本研究将对使用该疗法治疗慢性支气管炎的现有证据进行全面综述和评价。
本研究将为评估针灸治疗慢性支气管炎的有效性和副作用提供新的证据。由于数据并非针对个人,无需正式的伦理批准。
PROSPERO注册号:CRD42020170287。